RayKnowChina Research Map
Shortlist0

Not yet recruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07669740, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 15 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed gastric or gastroesophageal junction (GEJ)adenocarcinoma.

    Inclusion criterion 2

  3. Prior D2 radical gastrectomy with R0 resection.

    Inclusion criterion 4

    Disease recurrence during adjuvant chemotherapy or within 6 months after completion of adjuvant chemotherapy.

    Inclusion criterion 5

    Prior participation in another investigational drug study within 4 weeks prior to enrollment.

    Exclusion criterion 2

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

    Inclusion criterion 7

  5. At least one measurable lesion according to RECIST version 1.1.

    Inclusion criterion 6

  6. Active malignancy within the past 5 years, except for adequately treated in situ carcinoma or other cancers with a negligible risk of recurrence.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07669740, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years at the time of informed consent.
  • Histologically confirmed gastric or gastroesophageal junction (GEJ)adenocarcinoma.
  • HER2-negative disease, as determined by standard testing methods.
  • Prior D2 radical gastrectomy with R0 resection.
  • Disease recurrence during adjuvant chemotherapy or within 6 months after completion of adjuvant chemotherapy.
  • At least one measurable lesion according to RECIST version 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Adequate organ and bone marrow function.
  • Life expectancy of at least 3 months.
  • Ability to understand and willingness to sign written informed consent.

Exclusion Criteria:

  • Active malignancy within the past 5 years, except for adequately treated in situ carcinoma or other cancers with a negligible risk of recurrence.
  • Prior participation in another investigational drug study within 4 weeks prior to enrollment.
  • Symptomatic central nervous system (CNS) metastases.
  • Active autoimmune disease requiring systemic treatment.
  • Uncontrolled cardiovascular disease or uncontrolled hypertension.
  • History of thromboembolic events or clinically significant bleeding disorders within 6 months prior to enrollment.
  • Active tuberculosis or interstitial lung disease.
  • Known hypersensitivity to monoclonal antibodies or any excipients of the study drug.

Quoted from ClinicalTrials.gov, NCT07669740, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07669740, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07669740